India’s drugmakers are moving quickly into the booming global market for weight loss drugs, after local patent protection for semaglutide – the active ingredient in blockbuster treatments like Ozempic and Wegovy – ended. Generic versions are slashing treatment costs by as much as 70 per cent in some cases. However, questions remain over appropriate use and long-term effects. Ishan Garg reports for CNA. Subscribe to our channel here: https://cna.asia/youtubesub Visit our website: https://cna.